European Innovation Council

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

RespiQ is a healthtech startup that specializes in portable, non-invasive breath analysis technology aimed at the early detection and management of respiratory diseases. By utilizing advanced emission spectroscopy and artificial intelligence, RespiQ's device identifies volatile organic compounds (VOCs) in breath, enabling real-time detection of conditions such as COPD exacerbations. The company's focus on affordability, portability, and user-friendliness seeks to democratize access to advanced diagnostics, ultimately improving patient outcomes and reducing healthcare costs. In addition to respiratory diseases, RespiQ's versatile platform has potential applications for asthma, lung cancer, and infectious diseases. The company also offers an app that provides personalized health insights and dietary guidance, allowing users to monitor their health proactively. RespiQ's combination of technical and healthcare expertise positions it as a leader in breath diagnostics, with a commitment to enhancing overall health and well-being.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

Diagnostic of preterm birth risk and induction labor success probabilities through the use of torsional ultrasound technology

ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

ReLink is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge in hospital and homecare infusions.

Sunrise focuses on addressing the widespread issue of sleep disorders, particularly sleep apnea, which affects nearly one billion people globally. The company has developed a 3-gram sensor that provides a rapid, at-home diagnosis of sleep apnea, utilizing trigeminal drive analysis to detect respiratory events. This certified medical device connects seamlessly to a smartphone, allowing for easy use and immediate results. Clinical studies have demonstrated that Sunrise's technology matches the accuracy of traditional in-lab sleep studies but at a significantly lower cost. After testing, patients can consult with certified sleep doctors online or visit local sleep centers, streamlining the diagnostic process. With a large percentage of sleep apnea cases remaining undiagnosed, Sunrise offers a crucial solution for patients, caregivers, and insurers, enhancing the accessibility and efficiency of sleep disorder diagnostics.

iLoF, or Intelligent Lab on Fiber, is a developer of a digital health platform that utilizes advanced photonics and artificial intelligence to enhance personalized drug discovery and development. The company has created a patented system that identifies and captures unique features of gold-standard biomarkers, compiling this information into a cloud-based library. By leveraging this extensive database, iLoF aims to facilitate collaboration among physicists, biologists, and data scientists, ultimately improving the efficiency and patient-centricity of clinical trials. This innovative approach not only reduces the costs associated with drug development but also aims to provide patients with tailored, life-saving treatments.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Brainhero is a life science company that specializes in home-based neurofeedback therapy aimed at addressing neurological impairments, particularly Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). The company offers a playful approach to brain training, allowing children to learn how to control their brain activity through the measurement of brain waves using electroencephalogram (EEG) technology. This data is visualized in a user-friendly app, facilitating an engaging experience for young users. Brainhero's services extend beyond ASD and ADHD to include other neurological issues such as intellectual disabilities, epilepsy, and anxiety. Additionally, the company provides mobile neurofeedback training that helps improve concentration and relaxation, assisting medical practitioners in early detection of neurological problems and supporting appropriate medication management for patients.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

Afon Technology provides non-invasive blood glucose monitoring devices. Their services are non-invasive, pain-free, blood glucose tracking in real-time, continuous detection, potential pre-diabetic identification, alarm alerts, trend profiles, and time-in-range profiles, bluetooth connectivity to smart devices, ios, and android compatible stand-alone sensors, and user interface via app on smart device services.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing high-prevalence pathologies and unmet medical needs. The company focuses particularly on multiple sclerosis, offering diagnostic kits that facilitate early diagnosis of the condition. These kits are designed for seamless integration into the clinical routines of hospitals and medical centers, enabling healthcare professionals to deliver accurate results. By improving diagnostic capabilities, ALA Diagnostics aims to enhance the quality of life for individuals affected by multiple sclerosis. The company leverages collaborations with public organizations to foster innovative projects and enhance its product offerings.

Novus Diagnostics is focused on developing an innovative diagnostic device that addresses sepsis, a life-threatening condition caused by infections. The company's technology enables rapid detection and classification of pathogens directly from whole blood samples. By providing quick and automated pathogen identification in just minutes, Novus Diagnostics aims to enhance the ability of healthcare providers to treat patients efficiently and effectively, while also maintaining cost-effectiveness in the diagnostic process.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Diagnostic of preterm birth risk and induction labor success probabilities through the use of torsional ultrasound technology

Kahun operates an online medical platform designed to assist healthcare organizations in improving the clinical intake process. By leveraging artificial intelligence, the platform catalogs clinical information from peer-reviewed medical literature and extracts relevant insights to facilitate informed decision-making by physicians. This approach optimizes the time doctors spend on documentation while enhancing their overall understanding of clinical knowledge. Ultimately, Kahun aims to improve clinical outcomes by providing a transparent and explainable system that supports efficient and effective diagnosis.

Restore Medical is a medical device company focused on treating congestive heart failure, specifically targeting patients with left ventricle failure. Founded in 2016 and based in Or Yehuda, Israel, the company offers ContraBand, a catheter-delivered implant designed for placement in the pulmonary arteries. This innovative device aims to enhance left ventricle ejection fraction, decrease mitral regurgitation, and restore favorable ventricular geometry. By improving patient outcomes, Restore Medical's solutions contribute to a better quality of life and aim to reduce the rates of hospital readmission among affected individuals.

Idoven is a pioneering company that has created an innovative cardiology-as-a-service platform utilizing artificial intelligence to enhance the ability of both cardiologists and non-specialist clinicians to identify, triage, and diagnose heart conditions on a large scale. The platform analyzes long-duration electrocardiograms to detect alterations in cardiac electrical activity and arrhythmias, allowing for early diagnosis and prevention of serious cardiac diseases, including myocardial infarction and sudden death. Idoven collaborates with notable partners such as AstraZeneca, Abbott, and Google, and has received investments from prominent firms like Insight Partners and Northzone. The company has been recognized with several prestigious awards for its technology, including accolades from the European Innovation Council and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. Additionally, Idoven has been named one of the top 50 companies in Digital Health by CB Insights for 2023.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

PoroUS combines non-ionizing 3D ultrasound technology and image guidance with sophisticated spectral signal processing to ensure the osteoporosis diagnosis. PoroUS’ cortical ultrasound back-scatter analysis offers a novel way to detect microstructural changes (porosity and thickness) in the cortical bone. PoroUS provides a precision- and operating independence-tool, which will improve the cost effectiveness and reduce the economic burden by preventing fragility fractures.

Oivi is a company that specializes in developing an affordable AI-powered camera and platform for identifying diabetic eye diseases. Founded in 2017 and headquartered in Oslo, Norway, Oivi's technology enables retinal screening in primary care settings, helping to raise awareness and support the maintenance of eye health for individuals with diabetes. The platform features automated image capture and diagnostics, allowing for effective monitoring of eye conditions through teleconsultation. With a diverse team skilled in camera and software development, Oivi aims to facilitate early detection and prevention of diabetes-related vision loss, ultimately contributing to improved patient outcomes.

Hy2Care BV is a start-up based at the University of Twente in the Netherlands, focused on developing a groundbreaking treatment for osteoarthritis, a condition affecting over 100 million patients in the Western world. The company's primary product is an injectable hydrogel, designed to repair cartilage defects, particularly in the knee. This bioresorbable hydrogel consists of a two-component system made from natural polymer conjugates that undergo a mild enzymatic reaction to create a functional repair solution for cartilage damage. Hy2Care aims to significantly improve the quality of life for individuals suffering from osteoarthritis by providing an effective and innovative treatment option.

Dermagnostix is a German company founded in 2020, located in the Freiburg and Munich areas. It specializes in developing innovative dermatology diagnostics aimed at enhancing clinical practice and improving patient experiences. The company has created a molecular diagnostic platform that focuses on skin diseases, enabling rapid and objective differentiation between conditions such as eczema and psoriasis at a molecular level. This technology assists healthcare professionals in providing better care for their patients, ultimately aiming to improve outcomes in dermatological practice.

NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.

Thericon is a medical imaging company that provides multiparametric imaging technology for surgeries. The company helps surgeons improve accuracy and brings accurate information to the surgical procedure.

Aligned Bio specializes in the development of advanced nanowire biosensor platforms that cater to various industries, including biomedicine, water purification, public safety, and personal electronics. The company’s proprietary methods for nanowire production and alignment enhance the sensitivity and accuracy of its sensors, making them highly effective for applications such as disease diagnosis, pathogen identification, pesticide detection, and pollution monitoring. By leveraging the large area of nanowires and improved signal capacity, Aligned Bio enables sensor manufacturers to achieve superior performance at a reduced cost, positioning itself as a key player in the evolving biosensor and electronics markets.

BOYDSense is a company based in South San Francisco, California, that specializes in developing non-invasive tools for measuring critical biomarkers through exhaled breath. Founded in 2015, the company focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns in human breath. This innovative approach aims to simplify the monitoring, screening, and risk stratification of chronic conditions, enabling medical professionals to diagnose and manage diseases more effectively.

Sunrise focuses on addressing the widespread issue of sleep disorders, particularly sleep apnea, which affects nearly one billion people globally. The company has developed a 3-gram sensor that provides a rapid, at-home diagnosis of sleep apnea, utilizing trigeminal drive analysis to detect respiratory events. This certified medical device connects seamlessly to a smartphone, allowing for easy use and immediate results. Clinical studies have demonstrated that Sunrise's technology matches the accuracy of traditional in-lab sleep studies but at a significantly lower cost. After testing, patients can consult with certified sleep doctors online or visit local sleep centers, streamlining the diagnostic process. With a large percentage of sleep apnea cases remaining undiagnosed, Sunrise offers a crucial solution for patients, caregivers, and insurers, enhancing the accessibility and efficiency of sleep disorder diagnostics.

Criam is a biotechnology company based in Braga, Portugal, founded in 2015. It specializes in the research and development of a medical device designed for blood type analysis and the detection of infectious diseases. The company's flagship product offers rapid and accurate testing for various conditions, including HIV, Brucella, tick fever, syphilis, mononucleosis, and meningitis. This portable device operates independently of electricity or laboratory infrastructure, making it accessible for use in diverse environments. Additionally, Criam's technology is scalable, allowing a single reader to perform multiple tests using specific cartridges and advanced computer vision algorithms. By optimizing blood testing services, Criam aims to provide timely health information and improve clinical decision-making.

ReLink is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge in hospital and homecare infusions.

Aligned Bio specializes in the development of advanced nanowire biosensor platforms that cater to various industries, including biomedicine, water purification, public safety, and personal electronics. The company’s proprietary methods for nanowire production and alignment enhance the sensitivity and accuracy of its sensors, making them highly effective for applications such as disease diagnosis, pathogen identification, pesticide detection, and pollution monitoring. By leveraging the large area of nanowires and improved signal capacity, Aligned Bio enables sensor manufacturers to achieve superior performance at a reduced cost, positioning itself as a key player in the evolving biosensor and electronics markets.

Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.

Operator of a medical technology company intended to offer affordable EEG (electroencephalogram) scans and interpretations for epilepsy patients. The company provides an affordable, Bluetooth-enabled electrode cap to access and interpret medical information from the brain which is uploaded to the cloud, and offers remote diagnosis by neurologists, enabling patients in low- and middle-income countries to get diagnosed and treated for epilepsy.

PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.

Idoven is a pioneering company that has created an innovative cardiology-as-a-service platform utilizing artificial intelligence to enhance the ability of both cardiologists and non-specialist clinicians to identify, triage, and diagnose heart conditions on a large scale. The platform analyzes long-duration electrocardiograms to detect alterations in cardiac electrical activity and arrhythmias, allowing for early diagnosis and prevention of serious cardiac diseases, including myocardial infarction and sudden death. Idoven collaborates with notable partners such as AstraZeneca, Abbott, and Google, and has received investments from prominent firms like Insight Partners and Northzone. The company has been recognized with several prestigious awards for its technology, including accolades from the European Innovation Council and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. Additionally, Idoven has been named one of the top 50 companies in Digital Health by CB Insights for 2023.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

RadonTec GmbH, founded in 2017 and based in Wittislingen, Bayern, specializes in radon detection and control systems for radon-proof buildings. The company develops a Radon Detection and Control System (RDC) that employs a sensor network to actively monitor and manage ventilation systems or fans. In addition to its primary offerings, RadonTec provides services such as workplace and interior radon measurements, control measurements, and analysis of building materials. Their products include radiation measurement devices and accessories suitable for both residential and professional applications, aimed at ensuring safe environments in construction and occupancy.

GlucoModicum is a company that specializes in developing innovative technology for needle-free health and biomarker monitoring. It focuses on creating a glucose monitoring solution that utilizes precise magnetohydrodynamic technology. The company is working on wristwear equipped with a replaceable sensor that allows users to monitor their blood glucose levels without the need for needles. This system enables diabetic patients to easily track their health by syncing data with smartphones and uploading it to the cloud, facilitating effective self-management of blood glucose levels.

Glycanostics is a start-up company providing an early-stage cancer diagnostic test. They develop clinically validate and register an affordable, non-invasive next-gen liquid biopsy prostate cancer diagnostic test.

ADVITOS GmbH is a Munich-based company that specializes in the design, development, and marketing of extracorporeal multiple organ support therapies for hospitals in Germany. The company offers the ADVanced organ support treatment, a dialysis procedure that effectively removes a range of toxins from the liver, lungs, and kidneys, including water-soluble and protein-bound substances. The ADVOS method represents a pioneering approach to multi-organ support, combining the treatment of liver, lung, and kidney functions while also addressing acid-base balance. This method utilizes albumin dialysis to facilitate the fluid-based elimination of CO2, hepatic toxins, and nephrotoxins, correcting metabolic and respiratory acidosis without the need for gas exchangers. Founded in 2004, ADVITOS GmbH was previously known as Hepa Wash GmbH.

Idoven is a pioneering company that has created an innovative cardiology-as-a-service platform utilizing artificial intelligence to enhance the ability of both cardiologists and non-specialist clinicians to identify, triage, and diagnose heart conditions on a large scale. The platform analyzes long-duration electrocardiograms to detect alterations in cardiac electrical activity and arrhythmias, allowing for early diagnosis and prevention of serious cardiac diseases, including myocardial infarction and sudden death. Idoven collaborates with notable partners such as AstraZeneca, Abbott, and Google, and has received investments from prominent firms like Insight Partners and Northzone. The company has been recognized with several prestigious awards for its technology, including accolades from the European Innovation Council and the Healthy Longevity Catalyst Award from the US National Academy of Medicine. Additionally, Idoven has been named one of the top 50 companies in Digital Health by CB Insights for 2023.

MedTrace Pharma A/S, founded in 2015 and headquartered in Kongens Lyngby, Denmark, specializes in medical technology focused on improving positron emission tomography (PET) imaging. The company has developed an automated system, known as MT-100, which facilitates the bedside production and infusion of radioactive water, specifically 15O-water, into patients during PET scans. This innovative approach enhances the sensitivity of imaging results and significantly increases patient throughput. Complementing the MT-100 system is aQuant, an analytical software platform designed to interpret the PET scan data generated from the use of 15O-water. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace Pharma aims to advance clinical practices in diagnostic imaging through its cutting-edge technology.

Novus Diagnostics is focused on developing an innovative diagnostic device that addresses sepsis, a life-threatening condition caused by infections. The company's technology enables rapid detection and classification of pathogens directly from whole blood samples. By providing quick and automated pathogen identification in just minutes, Novus Diagnostics aims to enhance the ability of healthcare providers to treat patients efficiently and effectively, while also maintaining cost-effectiveness in the diagnostic process.

KinePict is a developer of advanced medical imaging technology focused on enhancing X-ray angiography. The company utilizes a patented kinetic imaging technique that captures motion-related functional information from X-ray image series. This process results in the creation of a new type of image known as contrast enhanced image (CEI) or digital variance angiography (DVA). KinePict's technology aims to make angiography safer by significantly reducing the amount of contrast medium and X-ray radiation exposure for both patients and healthcare professionals. By providing detailed insights into bodily functions and movements, KinePict supports healthcare providers in making more informed diagnoses.

KinePict is a developer of advanced medical imaging technology focused on enhancing X-ray angiography. The company utilizes a patented kinetic imaging technique that captures motion-related functional information from X-ray image series. This process results in the creation of a new type of image known as contrast enhanced image (CEI) or digital variance angiography (DVA). KinePict's technology aims to make angiography safer by significantly reducing the amount of contrast medium and X-ray radiation exposure for both patients and healthcare professionals. By providing detailed insights into bodily functions and movements, KinePict supports healthcare providers in making more informed diagnoses.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

ReLink is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge in hospital and homecare infusions.

ReLink is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge in hospital and homecare infusions.

SOMAprobes focuses on the development and commercialization of innovative diagnostic solutions that leverage the biology of nucleases. The company specializes in in vitro diagnostic tests aimed at identifying diseases that are often challenging to diagnose using traditional methods. Among its offerings are activatable contrast agents designed for MRI detection of bacterial pathogens, particularly at the onset of infectious diseases such as cancer, bone infections, and prosthetic joint infections. These advancements provide healthcare professionals with essential tools for rapid decision-making, improving patient outcomes through timely and accurate diagnosis.

MedTrace Pharma A/S, founded in 2015 and headquartered in Kongens Lyngby, Denmark, specializes in medical technology focused on improving positron emission tomography (PET) imaging. The company has developed an automated system, known as MT-100, which facilitates the bedside production and infusion of radioactive water, specifically 15O-water, into patients during PET scans. This innovative approach enhances the sensitivity of imaging results and significantly increases patient throughput. Complementing the MT-100 system is aQuant, an analytical software platform designed to interpret the PET scan data generated from the use of 15O-water. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace Pharma aims to advance clinical practices in diagnostic imaging through its cutting-edge technology.

MoveUP specializes in developing and commercializing digital therapeutic solutions aimed at enhancing patient rehabilitation. The company's closed-loop system promotes high compliance and improved outcomes by utilizing continuously collected data to tailor treatments to individual patients. Its inaugural therapy focuses on orthopaedic patients undergoing joint surgery, providing a personalized approach to recovery. MoveUP's platform includes user-friendly, medical-grade mobile applications designed to streamline and enhance the rehabilitation process, ultimately enabling faster recovery times for patients. The company holds CE medical device and ISO 13485 certifications, affirming its commitment to quality and regulatory standards in healthcare.

SOMAprobes focuses on the development and commercialization of innovative diagnostic solutions that leverage the biology of nucleases. The company specializes in in vitro diagnostic tests aimed at identifying diseases that are often challenging to diagnose using traditional methods. Among its offerings are activatable contrast agents designed for MRI detection of bacterial pathogens, particularly at the onset of infectious diseases such as cancer, bone infections, and prosthetic joint infections. These advancements provide healthcare professionals with essential tools for rapid decision-making, improving patient outcomes through timely and accurate diagnosis.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

Weber Hospital Systems is a company that specializes in developing solutions to help minimize healthcare-associated infections (HAIs) in hospitals. By developing innovative solutions to help reduce the risk of HAIs, Weber Hospital Systems is likely to play an important role in improving patient outcomes and overall hospital safety. Their solutions include a range of products such as disinfectant systems, air filtration systems, and surface coatings that are designed to eliminate or reduce the presence of harmful pathogens in the hospital environment. One of the company's flagship products is the Weber Mediclean System, a fully automated disinfection system that uses UV-C light to kill bacteria and viruses on hospital surfaces. This system is designed to be fast and efficient, eliminating up to 99.99% of bacteria and viruses within a matter of minutes. In addition to their disinfection systems, Weber Hospital Systems also offers air filtration systems that use advanced HEPA filtration technology to remove harmful particles and pathogens from the air. Their surface coatings are designed to create a barrier that prevents the growth of bacteria and viruses on hospital surfaces, providing an additional layer of protection against HAIs.

ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

Weber Hospital Systems is a company that specializes in developing solutions to help minimize healthcare-associated infections (HAIs) in hospitals. By developing innovative solutions to help reduce the risk of HAIs, Weber Hospital Systems is likely to play an important role in improving patient outcomes and overall hospital safety. Their solutions include a range of products such as disinfectant systems, air filtration systems, and surface coatings that are designed to eliminate or reduce the presence of harmful pathogens in the hospital environment. One of the company's flagship products is the Weber Mediclean System, a fully automated disinfection system that uses UV-C light to kill bacteria and viruses on hospital surfaces. This system is designed to be fast and efficient, eliminating up to 99.99% of bacteria and viruses within a matter of minutes. In addition to their disinfection systems, Weber Hospital Systems also offers air filtration systems that use advanced HEPA filtration technology to remove harmful particles and pathogens from the air. Their surface coatings are designed to create a barrier that prevents the growth of bacteria and viruses on hospital surfaces, providing an additional layer of protection against HAIs.

Xsensio is a digital health company focused on addressing the challenge of real-time, continuous monitoring of health parameters. It is developing an innovative Lab-on-Skin wearable device that serves as a miniaturized sensing platform, enabling continuous and real-time analysis of biochemical information at the skin's surface. This technology allows for the precise measurement of various health indicators, such as electrolytes, metabolites, hormones, and proteins, akin to traditional blood tests but in a minimally invasive manner. By providing unprecedented insights during critical health events, Xsensio aims to enhance patient care and shift the healthcare industry from a static to a dynamic approach in health monitoring.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

PKVitality is a bio-wearable company based in Paris, France, that specializes in developing innovative health monitoring devices. Its flagship product, K'Watch Glucose, is a smartwatch-style continuous glucose monitoring device that employs a micro-needle sensor to allow diabetics to monitor their glucose levels painlessly and discreetly. This wearable tracker is designed to provide real-time data without the need for calibration, offering a complete history of glucose levels and sending alerts for potential hypo or hyperglycemia episodes. Additionally, PKVitality is expanding its product line to include a Continuous Lactate Monitor and multi-analyte continuous monitors, which will further enhance the capabilities of their health monitoring technology. Founded in 2017, PKVitality aims to simplify health management for individuals, particularly those with diabetes, by eliminating the discomfort associated with traditional blood tests.

ADVITOS GmbH is a Munich-based company that specializes in the design, development, and marketing of extracorporeal multiple organ support therapies for hospitals in Germany. The company offers the ADVanced organ support treatment, a dialysis procedure that effectively removes a range of toxins from the liver, lungs, and kidneys, including water-soluble and protein-bound substances. The ADVOS method represents a pioneering approach to multi-organ support, combining the treatment of liver, lung, and kidney functions while also addressing acid-base balance. This method utilizes albumin dialysis to facilitate the fluid-based elimination of CO2, hepatic toxins, and nephrotoxins, correcting metabolic and respiratory acidosis without the need for gas exchangers. Founded in 2004, ADVITOS GmbH was previously known as Hepa Wash GmbH.

ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

MindPeak GmbH, founded in 2018 and headquartered in Hamburg, Germany, specializes in developing artificial intelligence software tools aimed at enhancing cancer diagnostics. The company's flagship product, BreastAI, facilitates the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. By automating tasks such as cell and biomarker quantification, MindPeak's solutions improve the efficiency of pathologists, allowing them to focus on critical decision-making in cancer treatment. The company also maintains a strategic relationship with Gestalt Diagnostics, further expanding its impact in the field of diagnostic automation. Through its innovative platform, MindPeak strives to make microscopical analysis more accessible and cost-effective in clinical environments.

Oivi is a company that specializes in developing an affordable AI-powered camera and platform for identifying diabetic eye diseases. Founded in 2017 and headquartered in Oslo, Norway, Oivi's technology enables retinal screening in primary care settings, helping to raise awareness and support the maintenance of eye health for individuals with diabetes. The platform features automated image capture and diagnostics, allowing for effective monitoring of eye conditions through teleconsultation. With a diverse team skilled in camera and software development, Oivi aims to facilitate early detection and prevention of diabetes-related vision loss, ultimately contributing to improved patient outcomes.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and based in Tirat Carmel, Israel. The company develops innovative diagnostic solutions aimed at improving patient care and reducing healthcare costs, particularly through the prevention of antibiotic misuse. MeMed's flagship products include MeMed BV, a test that differentiates between bacterial and viral infections, and the ImmunoDx platform, which utilizes proprietary biomarkers and algorithms to analyze the immune system's responses to pathogens. This technology addresses significant challenges in infectious disease diagnostics, providing rapid and actionable insights that enable healthcare providers to make informed decisions regarding antibiotic treatments. By accurately identifying infection sources, MeMed aims to combat the inappropriate prescription of antibiotics, which contributes to the emergence of resistant bacterial strains and incurs substantial costs to healthcare systems worldwide.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

Picterus is developing a smartphone application aimed at diagnosing jaundice in newborns, a condition that contributes to over 100,000 deaths annually, particularly in impoverished areas of Sub-Saharan Africa and South Asia. Existing screening devices are prohibitively expensive, often costing around $7,000, which limits access in low-resource settings. The app utilizes patented biomedical optics technology to provide accurate estimates of jaundice levels while accounting for variations in skin pigmentation. This innovation addresses the growing need for affordable and effective diagnostic tools, especially given the trend of shorter hospital stays post-birth and the rising rates of jaundice-related hospital readmissions. By enabling parents to monitor their child's jaundice levels at home, Picterus aims to improve health outcomes for vulnerable populations.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, specializing in the development of diagnostic products and services for liver cancer. Established in 2015, Ophiomics focuses on integrating bioinformatics, artificial intelligence, and genomics to enhance diagnostic and prognostic capabilities in oncology. The company is ISO 13485 and ISO 9001 certified, ensuring adherence to high-quality standards in its operations. Its product pipeline encompasses various stages of development, including pre-clinical programs and those undergoing clinical validation. Ophiomics aims to improve early detection of liver cancer through biomarker-based diagnostic devices that combine molecular signatures with clinical parameters in predictive algorithms, ultimately assisting healthcare providers in treatment selection and clinical follow-up for better patient outcomes.

MindPeak GmbH, founded in 2018 and headquartered in Hamburg, Germany, specializes in developing artificial intelligence software tools aimed at enhancing cancer diagnostics. The company's flagship product, BreastAI, facilitates the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. By automating tasks such as cell and biomarker quantification, MindPeak's solutions improve the efficiency of pathologists, allowing them to focus on critical decision-making in cancer treatment. The company also maintains a strategic relationship with Gestalt Diagnostics, further expanding its impact in the field of diagnostic automation. Through its innovative platform, MindPeak strives to make microscopical analysis more accessible and cost-effective in clinical environments.

Aiforia Technologies, founded in 2013 as a spin-off from the Finnish Institute for Molecular Medicine at the University of Helsinki, specializes in cloud-based microscopy and pathology. The company offers the Aiforia® Platform, which combines deep learning artificial intelligence with high-performance cloud computing to enhance image-based diagnostics. Aiforia's solutions aim to increase efficiency and scalability in medical image analysis, supporting pathologists and scientists in both preclinical and clinical settings. By providing highly accurate and consistent data, Aiforia facilitates new discoveries and clinical decision-making across various disciplines, including oncology and neuroscience. The platform's image-agnostic capabilities allow it to extend its applications beyond traditional boundaries, positioning Aiforia as a leader in advancing medical imaging technology.

Imaqen Ltd. is a Finnish healthcare technology company developing a new pre-screening solution for early detection of cancer. The innovation offers a non-invasive patient examination and it is suitable for use in wide range of healthcare facilities. The utilised method is protected by patents. Their team consists of experienced diagnostic imaging and clinical research professionals with solid track records in successful product development and global sales and marketing.

Medicortex Finland is developing the first, non-invasive, point-of-care diagnostic test for Traumatic Brain Injury and concussion. Problem: A Traumatic Brain Injury (TBI) happens when an external force to the head causes damage to the brain tissue. Mild TBI, which is also known as concussion, is difficult to diagnose with current diagnostic methods such as CT and MRI scans. Solution: Medicortex is working towards the incorporation of brain injury biomarkers into a hand-held diagnostic kit, which will give a reliable result rapidly and will not require medical professionals to interpret the result. Business: We identified a unique biomarker that can be detected from urine and saliva. With strong clinical evidence and protected idea, we are willing to negotiate with bigger diagnostic companies for collaboration on manufacturing and distribution. Market: Customers include hospitals, emergency rooms, paramedics and first responders, military paramedics, sports teams (especially contact sports such as rugby, American football, ice hockey), schools, pharma and insurance companies. Accomplishments: We have completed three clinical trials which have demonstrated the ability of the proprietary biomarker to distinguish TBI patients from healthy controls. The company has received grant funding from US Department of Defense (twice), European Union and Finnish Government.

Started in 2001, JSC Baltic Orthoservice, better known by its brand name Ortho Baltic, has grown into one of the biggest producers of individual orthopedic devices in Europe. Whole company‘s activity is about custom-made products for the foot. We combine the expertise of footwear technicians, footwear engineers-technologists, physicians, orthopaedists, and IT engineers. The modern technologies such as human body scan, computer designing of production forms, CAM carving and our own unique business management software are employed. Our clients, B2B companies, are offered the complete solution for serving their own patients that includes our know-how, online ordering system, all stages of design and production, quick service and the possibility to use our 3D lower limb scanning systems. By offering the execution of all production stages in one company – guarantees a perfect final result, since the requirements for the entire production cycle are known from the very beginning.

Started in 2001, JSC Baltic Orthoservice, better known by its brand name Ortho Baltic, has grown into one of the biggest producers of individual orthopedic devices in Europe. Whole company‘s activity is about custom-made products for the foot. We combine the expertise of footwear technicians, footwear engineers-technologists, physicians, orthopaedists, and IT engineers. The modern technologies such as human body scan, computer designing of production forms, CAM carving and our own unique business management software are employed. Our clients, B2B companies, are offered the complete solution for serving their own patients that includes our know-how, online ordering system, all stages of design and production, quick service and the possibility to use our 3D lower limb scanning systems. By offering the execution of all production stages in one company – guarantees a perfect final result, since the requirements for the entire production cycle are known from the very beginning.